



HOOKIPA TO PRESENT AT BIO EQUITY EUROPE 2014

Vienna, Austria, April 22, 2014 – Hookipa Biotech AG, today announced that the company's Chief Executive Officer, Dr. Katherine Cohen, will provide an overview of the company's technologies and programs at the BIO Equity Europe 2014 (Amsterdam, The Netherlands, May 21-22; presentation on Wednesday, May 21, at 5:00 p.m. CET).

About Hookipa Biotech

Hookipa Biotech AG is developing a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology. The Vaxwave® technology is a novel vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. The platform is one of the most promising new technologies for next generation vaccines due to its ability to stimulate both potent B-cell and CD8+ T-cell immune responses. Vaxwave® has been validated in various disease models. Unlike other vectors, Vaxwave® vaccines can be administered repeatedly to boost the immune system. The Company is focused on the development of its lead vaccine candidate HB101, a vaccine for immunization against cytomegalovirus (CMV) and plans to further industrialize the Vaxwave® technology and build a robust product pipeline in the area of infectious diseases and cancer. Hookipa has raised a total of EUR 27 million in equity finance from internationally renowned venture capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.

Contact:

Dr. Katherine Cohen
Chief Executive Officer

Hookipa Biotech AG
Helmut-Qualtinger-Gasse 2
1030 Vienna
Austria
Email: office@hookipabiotech.com